PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31833760-1	2020	Tofacitinib is an orally administered medication with a mechanism of action that involves JAK1, JAK2, JAK3 and TYK2 pathway inhibition.	tofacitinib	0-11	tyrosine kinase 2	Homo sapiens	111-115	
20478313-2	2010	Although the crystal structures of active JAK1 and JAK2 kinase domains have been reported recently with the clinical compound CP-690550, the structures of both TYK2 and JAK3 with CP-690550 have remained outstanding.	tofacitinib	179-188	tyrosine kinase 2	Homo sapiens	160-164	
32657836-5	2020	An analysis of such disease-associated loci elucidated potential drug targets (e.g., TYK2 targeted by tofacitinib).	tofacitinib	102-113	tyrosine kinase 2	Homo sapiens	85-89	
31288716-1	2019	The search for inhibitors of the Janus kinase family (JAK1, JAK2, JAK3 and TYK2) has been ongoing for several decades and has resulted in a number of JAK inhibitors being approved for use in patients, such as tofacitinib for the treatment of autoimmune diseases such as Rheumatoid Arthritis (RA).	tofacitinib	209-220	tyrosine kinase 2	Homo sapiens	75-79	
30806707-2	2019	Tofacitinib is a selective JAK1, 3 inhibitor with less activity against JAK2 and TYK2 and baricitinib is a selective, oral JAK1, 2 inhibitor with moderate activity against TYK2 and significantly less activity against JAK3.	tofacitinib	0-11	tyrosine kinase 2	Homo sapiens	81-85	
28790099-2	2017	Tofacitinib inhibits cytokine signalling through blockade of JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2).	tofacitinib	0-11	tyrosine kinase 2	Homo sapiens	82-99	
28790099-2	2017	Tofacitinib inhibits cytokine signalling through blockade of JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2).	tofacitinib	0-11	tyrosine kinase 2	Homo sapiens	101-105